4SC treats first patient in Phase I TOPAS study
4SC-202 is a benzamide type selective inhibitor of human class I histone deacetylases (HDAC) isoenzymes 1, 2 and 3. TOPAS is a mono-centric, single arm, open-label dose escalation
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).